Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Enoxaparin vs ENOXAPARIN SODIUM (PRESERVATIVE FREE)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients at risk for thromboembolic complications,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) with aspirin,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (Cr Cl <30 m L/min).
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Enoxaparin is primarily metabolized in the liver via desulfation and depolymerization, with some renal clearance. It does not rely on cytochrome P450 enzymes.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
Approximately 92-95% bound to antithrombin III (ATIII) and other plasma proteins.
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
0.10-0.13 L/kg; confined primarily to intravascular space, indicating limited extravascular distribution.
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
Subcutaneous: Approximately 92-100% absorbed; intravenous administration yields 100% bioavailability.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis: 30 mg subcutaneously once daily. Not recommended if Cr Cl <15 m L/min.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No specific dose adjustment guidelines for hepatic impairment; use with caution in severe hepatic impairment due to increased bleeding risk.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Dose based on age: neonates and infants <2 months: 1.5 mg/kg subcutaneously every 12 hours; children ≥2 months: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours.
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
Increased risk of bleeding, especially in elderly ≥75 years; consider dose reduction and monitor renal function and anti-Xa levels. For treatment in elderly ≥75 years: 1 mg/kg subcutaneously every 12 hours; no routine dose reduction but caution advised.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Spinal/epidural hematomas may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of other anticoagulants, or history of spinal surgery/deformity. Monitor for signs of neurological impairment and manage emergently.
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Risk of spinal/epidural hematoma with neuraxial procedures,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or concurrent use of anticoagulants/antiplatelets,Heparin-induced thrombocytopenia (HIT) possible; monitor platelet counts,Use with caution in patients with bleeding disorders, uncontrolled hypertension, or recent surgery,Not interchangeable with other heparins (unit-for-unit)
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
Active major bleeding,History of immune-mediated heparin-induced thrombocytopenia (HIT) within 100 days,Known hypersensitivity to enoxaparin, heparin, or pork products,Concomitant use with other anticoagulants (except under close monitoring)
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
No specific food restrictions. Avoid excessive consumption of alcohol (may increase bleeding risk). Maintain adequate vitamin K intake, but avoid sudden large changes.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no known teratogenic effects. Second trimester: no known fetal harm. Third trimester: risk of maternal hemorrhage, which may indirectly affect fetus; use with caution.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
Enoxaparin is excreted into breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.04. It is considered compatible with breastfeeding due to poor oral bioavailability in the infant. No adverse effects reported.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
Pregnancy increases plasma volume and renal clearance, leading to decreased peak anti-Xa levels and half-life. Dose adjustments may be needed to maintain therapeutic levels, especially in the third trimester. Weight-based dosing is recommended and may require upward titration. Anti-Xa monitoring is advised to guide dose adjustments. No standard fixed dose adjustment; individualize based on anti-Xa levels and clinical response.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Enoxaparin is a low molecular weight heparin (LMWH) preferred over unfractionated heparin for VTE prophylaxis due to predictable pharmacokinetics and no need for routine a PTT monitoring. Adjust dose for renal impairment (Cr Cl <30 m L/min). Protamine sulfate partially reverses (about 60%) its anticoagulant effect. Monitor for signs of bleeding, especially in elderly, low body weight (<45 kg), or those on antiplatelet agents. Avoid intramuscular injections. Spinal/epidural hematoma risk with neuraxial anesthesia; remove catheter at least 12 hours after last dose (24 hours if therapeutic dose).
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
Take exactly as prescribed; do not skip doses.,Inject subcutaneously in the fatty tissue of the abdomen, alternating sides.,Do not rub the injection site after administration.,Report any unusual bleeding or bruising, blood in urine or stool, or coughing up blood.,Avoid aspirin or NSAIDs unless directed by your doctor.,Seek immediate medical attention for severe headache, back pain, or neurological symptoms (signs of spinal hematoma).,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.,Do not stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Enoxaparin vs ENOXAPARIN SODIUM (PRESERVATIVE FREE), answered by our medical review team.
Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Enoxaparin and ENOXAPARIN SODIUM (PRESERVATIVE FREE) depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. The standard adult dose of ENOXAPARIN SODIUM (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Enoxaparin and ENOXAPARIN SODIUM (PRESERVATIVE FREE) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is classified as Category A/B. Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no kno. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.